HPV vaccineVaccine - HPV; Immunization - HPV; Gardasil; HPV2; HPV4; Vaccine to prevent cervical cancer; Genital warts - HPV vaccine; Cervical dysplasia - HPV vaccine; Cervical cancer - HPV vaccine; Cancer of the cervix - HPV vaccine; Abnormal Pap smear - HPV vaccine; Vaccination - HPV vaccine
All content below is taken in its entirety from the CDC HPV (Human Papillomavirus) Vaccine Information Statement (VIS): www. cdc. gov/vaccines/hcp/vi...Read Article Now Book Mark Article
Cervical cancer is cancer that starts in the cervix. The cervix is the lower part of the uterus (womb) that opens at the top of the vagina.Read Article Now Book Mark Article
Genital warts are soft growths on the skin and mucous membranes of the genitals. They may be found on the penis, vulva, urethra, vagina, cervix, and...Read Article Now Book Mark Article
HPV has also been linked to other kinds of cancers, including vaginal, vulvar, penile, anal, mouth, and throat cancers.
HPV is a common virus that is spread through sexual contact. There are several types of HPV. Many types don't cause problems. However, some types of HPV can cause cancers of the:
- Cervix, vagina, and vulva in women
- Penis in men
- Anus in women and men
- Back of the throat in women and men
The HPV vaccine protects against the types of HPV that cause most cases of cervical cancer. Other less common types of HPV can also cause cervical cancer.
The vaccine does not treat cervical cancer.
WHO SHOULD GET THIS VACCINE
The HPV vaccine is recommended for boys and girls 9 through 14 years old. The vaccine is also recommended for people up to 26 years old who haven't already gotten the vaccine or finished the series of shots.
Certain people between the ages of 27-45 may be candidates for the vaccine. Talk to your health care provider if you think you are a candidate in this age group.
The vaccine can offer protection against HPV-related cancers in any age group. Certain people who may have new sexual contacts in the future and could be exposed to HPV should also consider the vaccine.
HPV vaccine is given as a 2-dose series to boys and girls 9 through 14 years old:
- First dose: now
- Second dose: 6 to 12 months after the first dose
The vaccine is given as a 3-dose series to people 15 through 26 years old, and to those who have weakened immune systems:
- First dose: now
- Second dose: 1 to 2 months after the first dose
- Third dose: 6 months after the first dose
Pregnant women should not receive this vaccine. However, there have been no problems found in women who received the vaccine during pregnancy before they knew they were pregnant.
WHAT ELSE TO THINK ABOUT
The HPV vaccine does not protect against all types of HPV that can lead to cervical cancer. Girls and women should still receive regular screening (Pap test) to look for precancerous changes and early signs of cervical cancer.
The Pap test checks for cervical cancer. Cells scraped from the opening of the cervix are examined under a microscope. The cervix is the lower part...Read Article Now Book Mark Article
The HPV vaccine does not protect against other infections that can be spread during sexual contact.
Talk to your provider if:
- You are not sure whether you or your child should receive the HPV vaccine
- You or your child develops complications or severe symptoms after getting an HPV vaccine
- You have other questions or concerns about the HPV vaccine
Centers for Disease Control and Prevention website. HPV (Human Papillomavirus) VIS. www.cdc.gov/vaccines/hcp/vis/vis-statements/hpv.html. Updated October 30, 2019. Accessed February 7, 2020.
Kim DK, Hunter P. Advisory Committee on Immunization Practices recommended immunization schedule for adults aged 19 years or older - United States, 2019. MMWR Morb Mortal Wkly Rep. 2019;68(5):115-118. PMID: 30730868 www.ncbi.nlm.nih.gov/pubmed/30730868.
Robinson CL, Bernstein H, Romero JR, Szilagyi P. Advisory Committee on Immunization Practices recommended immunization schedule for children and adolescents aged 18 years or younger - United States, 2019. MMWR Morb Mortal Wkly Rep. 2019;68(5):112-114. PMID: 30730870 www.ncbi.nlm.nih.gov/pubmed/30730870.
Review Date: 1/1/2020
Reviewed By: John D. Jacobson, MD, Professor of Obstetrics and Gynecology, Loma Linda University School of Medicine, Loma Linda Center for Fertility, Loma Linda, CA. Also reviewed by David Zieve, MD, MHA, Medical Director, Brenda Conaway, Editorial Director, and the A.D.A.M. Editorial team.